Background: Demographic, socioeconomic, and cultural factors account for variation in global incidence trends of ovarian malignancy. Indian cancer registry statistics revealed equally wide interstate variations and prompted us to rethink on variations in screening techniques between different population groups. The present study was undertaken to verify the feasibility and effectiveness of Risk of Malignancy Index (RMI) and cancer antigen (CA) 125 in women residing in North India and place their screening results in the context of literature relevant to geographic and ethnic variations.
A detailed analysis of cancer registries in India highlights wide interstate variation in ovarian cancer rates. 7, 8 In parallel, international demographics emphasize the differences in global incidence patterns and correlate them with environmental or cultural risk factors. Thus, etiological factors and incidence trends vary between geographical areas inhabited by unique ethnic groups. 2, 9 This prompted us to rethink on the variations in screening modalities between different population groups.
We decided to concentrate on CA-125 and RMI as they are commonly used and easily reproducible. The CA-125 is the most well-known and widely accepted tumor marker for ovarian cancer. The glycoprotein concentration (normal <35 IU/mL) values are raised in 30 to 50% of cases of earlystage ovarian cancer and 80% of women with advanced 1% of healthy women, fluctuate during menstrual cycles, and are raised in many benign conditions like pelvic inflammatory disease, endometriosis, fibroid uterus, ulcerative colitis, liver cirrhosis, pleural, and pericardial effusion. 11 Therefore, as an individual test, it is not sufficient for preoperative triage. 12 Various combined methods for evaluating the risk of ovarian cancer in women have been proposed and validated over the last two decades. 13 Risk of Malignancy Index was originally developed in 1990 and predicted the chance of cancer based on menopausal status, ultrasound, and CA-125. 14 A number of modifications to the RMI have been proposed improving the accuracy of score:
• RMI 1 = U × M × CA-125, where a total ultrasound score of 0 made U = 0, a score of 1 made U = 1, and a score of ≥ 2 made U = 3; premenopausal status made M = 1; and postmenopausal M = 3. The serum level of CA-125 was applied directly to the calculation.
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• RMI 2 = U × M × CA-125, where a total ultrasound score of 0 or 1 made U = 1, and a score of ≥ 2 made U = 4; premenopausal status made M = 1; and postmenopausal M = 4. The serum level of CA-125 was applied directly to the calculation. 15 • RMI 3 = U × M × CA-125, where a total ultrasound score of 0 or 1 made U = 1, and a score of ≥ 2 made U = 3; premenopausal status made M = 1; and postmenopausal M = 3. The serum level of CA-125 was applied directly to the calculation. 16 • RMI 4 = U × M × S (size in centimeters) × CA-125, where a total ultrasound score of 0 or 1 made U = 1, and a score of ≥ 2 made U = 4. Premenopausal status made M = 1 and postmenopausal status made M = 4. A tumor size (single greatest diameter) of <7 cm made S = 1, and ≥ 7 cm made S = 2. The serum level of CA-125 was applied directly to the calculation. 17 Different versions of RMI have been validated retrospectively and prospectively in different clinical studies. 18 The Royal College of Obstetricians and Gynecologists (RCOG) suggests that a cut-off value of 200 demonstrates high degree of sensitivity and specificity for distinction between benign and malignant masses (sensitivity 51-90%, specificity 51-97%). In contrast, the IOTA group recommended an optimum cut-off value of 100 for clinical use. 12 Consequently, an ideal cut-off value of RMI for clinical application still needs to be assessed. Therefore, the present study was planned to retrospectively verify the effectiveness of RMI and CA-125 in distinguishing between benign and malignant ovarian masses, allowing local variations in CA-125 assays and ultrasound expertise in day-to-day practice. A relevant distinction from prior investigations will be our endeavor to focus the research on women residing in North India and place it in context of literature relevant to geographic and ethnic variations. The study was approved by the Institutional Ethical Committee. All women (age >30 years) having an adnexal mass planned for laparotomy were included in the study. Patients with incomplete medical records and those with preoperative histological diagnosis of malignant ovarian tumor were excluded from the study. Detailed clinical profile, including symptoms (local and systemic), duration of symptoms, and relevant history, was noted for each patient. Women were considered postmenopausal if they had at least 1 year of amenorrhea not related to other conditions or if they were 50 years old and had undergone a prior hysterectomy. All other women were considered premenopausal.
MATERIALS AND METHODS
Serum CA-125 levels (performed using electrochemiluminescence immunoassay) were measured preoperatively. 19 Ultrasonography was performed transvaginally by a 7.5 MHz transducer. A transabdominal repeat examination with a full bladder was obtained if a mass was found to be too large to be observed completely by vaginal route. A score was assigned for the following ultrasound features suggestive of malignancy: The presence of a multilocular cystic lesion, solid areas, bilateral lesions, ascites, and intraabdominal metastasis scored as one point for each. Thus, a total score (RMI 2) was calculated for each patient. 16 The histopathological diagnosis was considered the gold standard for definite outcome. 17 When a borderline ovarian tumor was found, it was classified as malignant ovarian tumor. 20 Statistical analysis was performed using Statistical Package for the Social Sciences, version 20. Receiver operating characteristic (ROC) curves were used for evaluating the performance of serum CA-125 and RMI as predictive tests for malignancy. The best cut-off values of the models were calculated in consideration of sensitivity, specificity, positive predictive value, and negative predictive value.
RESULTS
A total of 78 women were included in the analysis. The mean age of patients was 33. Further interviewing revealed that women had delayed presentation to the clinic even though they were symptomatic for more than 1 year (mean duration of symptoms was 16 months).
Of note, only 73 patients had tumors of ovarian origin. The remaining five patients had intraoperative surprises consisting of three mesenteric cysts, one appendicular tumor, and one large subserosal fibroid. After surgical resection and histopathological examination, 16 patients had malignant and 63 had benign diseases. The detailed description of tumor histology is mentioned in Table 1 . Statistically significant differences were found regarding age, menopausal status, ultrasound score, serum CA-125 and RMI between the groups with benign and malignant pathology ( Table 2 ).
In the ROC curve evaluation, CA-125 levels and RMI were found to be relevant predictors of malignancy (Graphs 1 and 2). The sensitivity, specificity, positive predictive value, and negative predictive value of CA-125 and RMI at the prevalidated cut-off values are depicted in Table 3 . By using a cut-off level of 35, serum CA-125 had a sensitivity of 75%, specificity of 76.2%, positive predictive value of 47.4%, and negative predictive value of 91.4%. In contrast, RMI had a sensitivity of 87.5%, specificity of 91.3%, positive predictive value of 73.6%, and negative predictive value of 96.5%.
Graph 1:
Receiver operating characteristic curve depicting the relationship between sensitivity and specificity of serum levels of CA-125 in the discrimination of malignant and benign pelvic masses Graph 2: Receiver operating characteristic curve depicting the relationship between sensitivity and specificity of RMI for discrimination between benign and malignant pelvic masses. Area under curve = 0.94 
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Hence, serum CA-125 levels failed to predict nearly one-fourth of the pelvic masses correctly and the retrospective corelation highlighted a false-positive rate of 24.1% and a false-negative rate of 25%. In comparison, RMI had significantly better predictive accuracy with a false-positive rate of 8.6% and a false-negative rate of 12.5%. Among the various histological types, serous cystadenoma accounted for most false-positive and mucinous cystadenocarcinoma was underlying most false-negative cases. This difference did not reach any statistical significance due to the small sample size of the study population.
DISCUSSION
Approximately 20% of women will develop a pelvic mass in their lifetime. 21 Ovarian pathology is responsible for 70% pelvic masses found at exploratory laparotomy on patients with preoperative diagnosis of adnexal masses not attributable to fibroids. 22 However, there is no effective screening method to timely detect cancer and improve clinical outcome. Subsequently, majority of women (60%) present with advanced disease and poor prognosis. The 5-year survival rate in all cases is 29% with median survival being 14 months only. 4, 5, 23 Survival in women with ovarian cancer is not only dependent on the stage of disease but also on the treating surgeon and the treatment facility. 24, 25 There is a statistically significant difference in the 5-year survival rates between patients being treated by high-volume physicians who perform surgery frequently, administer correct chemotherapy, and deliver appropriate treatment to ovarian cancer patients vis-à-vis low-volume physicians. 26 Despite the clear benefits of referral to gynecologic oncologists, more than 50% of patients are not referred to higher centers and lack preoperative triaging. 27, 28 For triage, epidemiological and genetic risk factors, evaluation of clinical signs and symptoms with careful selection, and interpretation of diagnostic tests should be individualized to each clinical context. 29 For this reason, it is imperative to ascertain the variations of commonly used screening modalities for distinct ethnic groups which share common genetic backgrounds, cultural traditions, reproductive beliefs, and dietary practices. Our study validates the use of CA-125 and RMI for North Indian women and emphasizes that both of these would be excellent screening tools dependent on availability. For appropriate triage and referral, all tiers of health care workers can be trained to interpret the results and make timely referrals to tertiary care centers. Clearly, serum CA-125 levels at a cut-off value of 35 IU/mL have a positive correlation with malignant histopathological findings with nearly similar sensitivity 75% and specificity 76.2%, but noticeably low positive predictive value of 47.41% and high negative predictive value of 91.4%. In remote areas, where sonographic facilities are limited, serum samples could be collected and transported to tertiary centers for measurement of CA-125 levels. Although the false-positive and falsenegative rates are high, serial levels could be researched further to improve the positive predictive value of the test.
Next, RMI cut-off of above 200 revealed an improved sensitivity (87.5%), specificity (91.3%), positive predictive value (73.6%), and negative predictive value (96.5%) when compared with CA-125. If all strata of health care professional learn to interpret ultrasound images and reports along with CA-125 and calculate RMI, the falsenegative rate would decline to half (24.1-12.5%) and falsepositive rate to one-fourth of the previous rate (25-8.6%). The performance of RMI recognized in the present study is comparable to researchers in other parts of the world. Research articles reviewed in Table 4 distinctly bring forth high negative predictive values and sensitivity of RMI all over the globe with frequently low positive predictive value. To the best of authors' knowledge, it is the first attempt to understand distinct patterns and cut-offs in communities populating different countries. However, there is a markedly wide variation in the performance of RMI (cut-off 200) in scientists working in the same geographical area. We believe that these differences may be attributed to lack of sufficient information on participant composition in the populations under study. Further, no discernible correlations were apparent in the detection capabilities of RMI in the same region or in-between regions. This may be explained by relatively small sample size in the observation studies. Moreover, imaging modalities have advanced over years effecting the sensitivity and specificity of sonographic parameters and eventually influencing the consistency in reporting from 1990 to 2017. Nevertheless, all researchers verified that RMI is a feasible tool useful all over the world.
Despite a promising performance of RMI at a cut-off of 200, some authors have shifted their focus to selecting a different cut-off for RMI (125-265). However, lowering the cut-off to 125 or elevating it to 265 did not bring any distinct improvement in the performance of RMI (Table 5) . 
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It is more important to draw the ideology of this argument and explore different cut-off levels for different ethnic groups residing in particular geographic locales. This will require dedicated documentation and publication of RMI values from gyne-oncology centers across the world. Further, statistical input from experts can help define ideal RMI cut-offs for each population. Based on the review, it is definite that we need to find answers to questions, such as: Are tumor markers dependent on genetic makeup? Is it possible that tumor characteristics depend on geographic areas? Do we need to develop specific screening guidelines based on ethnicity or domicile? Do groups with high-risk behaviors need different RMI cut-offs for early detection? At the moment, there is paucity of data to comment anything substantial in relation to any of these questions.
We acknowledge that the research has three pertinent limitations. Firstly, we have analyzed data from 78 women, which is a small sample size but it definitely adds to the growing pool of data from the Indian subcontinent. Secondly, although the research findings were comparable to previous studies from different parts of the world, we have grouped all our patients under a single umbrella of "North Indian" women. We aim to delve deeper and draw definite patterns in distinctive geographic or ethnic groups which reside in northern parts of India, as we collect and analyze more data in our ongoing study. Thirdly, the review of world literature is limited as articles in languages other than English are not included due to limited funding for translation.
CONCLUSION AND FUTURE PROSPECTS
The debate on the ideal screening method is ongoing, and despite many tools and algorithms, there is no consensus in the best possible technique for clinical practice. In future, the focus needs to be shifted away from the best screening tool to the development of individual cut-offs for homogenous populations. So far, no studies have specifically concentrated on stratification of screening tool cut-offs customized to distinctive ethnic groups. To add to this dilemma, we could not draw any conclusions from figures obtained from all over the world. However, we anticipate that due to our emphasis on commonly used screening tools, our findings have strong potential to influence clinical practice and encourage gynecologists from different countries to document data pertaining to RMI and CA-125. In the future, meticulous documentation of CA-125 and RMI scores will help to formulate robust evidence-based cut-off values for every ethnic and geographical group.
